Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 480

1.

Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.

Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, Fouladbakhsh JM, Gil B, Hershman DL, Mansfield S, Mussallem DM, Mustian KM, Price E, Rafte S, Cohen L.

J Clin Oncol. 2018 Jun 11:JCO2018792721. doi: 10.1200/JCO.2018.79.2721. [Epub ahead of print]

PMID:
29889605
2.

Reply to S.D. Lucio.

Lyman GH, Zon R, Harvey RD, Schilsky RL.

J Clin Oncol. 2018 Jul 10;36(20):2127. doi: 10.1200/JCO.2018.79.1780. Epub 2018 May 30. No abstract available.

PMID:
29847292
3.

Rationale, Opportunities, and Reality of Biosimilar Medications.

Lyman GH, Zon R, Harvey RD, Schilsky RL.

N Engl J Med. 2018 May 24;378(21):2036-2044. doi: 10.1056/NEJMhle1800125. No abstract available.

PMID:
29791832
4.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH.

J Clin Oncol. 2018 May 22:JCO2018788604. doi: 10.1200/JCO.2018.78.8604. [Epub ahead of print]

PMID:
29787356
5.

Integrative omics to detect bacteremia in patients with febrile neutropenia.

Kelly RS, Lasky-Su J, Yeung SJ, Stone RM, Caterino JM, Hagan SC, Lyman GH, Baden LR, Glotzbecker BE, Coyne CJ, Baugh CW, Pallin DJ.

PLoS One. 2018 May 16;13(5):e0197049. doi: 10.1371/journal.pone.0197049. eCollection 2018.

6.

Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis.

Kohn CG, Lyman GH, Beyer-Westendorf J, Spyropoulos AC, Bunz TJ, Baker WL, Eriksson D, Meinecke AK, Coleman CI.

J Natl Compr Canc Netw. 2018 May;16(5):491-497. doi: 10.6004/jnccn.2018.7008.

PMID:
29752323
7.

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M.

J Clin Oncol. 2018 Jul 10;36(20):2017-2023. doi: 10.1200/JCO.2018.78.8034. Epub 2018 May 10.

PMID:
29746227
8.

Evolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safety.

Kuderer NM, Lyman GH.

J Clin Oncol. 2018 Jun 20;36(18):1773-1776. doi: 10.1200/JCO.2018.78.5592. Epub 2018 May 9. No abstract available.

PMID:
29742010
9.

Immune-related Adverse Events in Cancer Patients.

Pallin DJ, Baugh CW, Postow MA, Caterino JM, Erickson TB, Lyman GH.

Acad Emerg Med. 2018 May 5. doi: 10.1111/acem.13443. [Epub ahead of print]

PMID:
29729100
10.

Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer.

Lyman GH, Culakova E, Poniewierski MS, Kuderer NM.

Thromb Res. 2018 Apr;164 Suppl 1:S112-S118. doi: 10.1016/j.thromres.2018.01.028.

PMID:
29703467
11.

Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer.

Denduluri N, Lyman GH, Wang Y, Morrow PK, Barron R, Patt D, Bhowmik D, Li X, Bhor M, Fox P, Dhanda R, Saravanan S, Jiao X, Garcia J, Crawford J.

Clin Breast Cancer. 2018 Feb 16. pii: S1526-8209(17)30508-6. doi: 10.1016/j.clbc.2018.02.003. [Epub ahead of print]

12.

Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.

Li A, Garcia DA, Lyman GH, Carrier M.

Thromb Res. 2018 Mar 2. pii: S0049-3848(18)30216-0. doi: 10.1016/j.thromres.2018.02.144. [Epub ahead of print]

13.

Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study.

Panattoni L, Fedorenko C, Greenwood-Hickman MA, Kreizenbeck K, Walker JR, Martins R, Eaton KD, Rieke JW, Conklin T, Smith B, Lyman G, Ramsey SD.

J Oncol Pract. 2018 Mar;14(3):e176-e185. doi: 10.1200/JOP.2017.028191. Epub 2018 Feb 8.

PMID:
29452549
14.

American Society of Clinical Oncology Statement: Biosimilars in Oncology.

Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL.

J Clin Oncol. 2018 Apr 20;36(12):1260-1265. doi: 10.1200/JCO.2017.77.4893. Epub 2018 Feb 14.

PMID:
29443651
15.

Oncology Clinical Pathways: Charting the Landscape of Pathway Providers.

Daly B, Zon RT, Page RD, Edge SB, Lyman GH, Green SR, Wollins DS, Bosserman LD.

J Oncol Pract. 2018 Mar;14(3):e194-e200. doi: 10.1200/JOP.17.00033. Epub 2018 Feb 7. No abstract available.

PMID:
29412768
16.

Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.

Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH.

BMC Cancer. 2018 Jan 6;18(1):44. doi: 10.1186/s12885-017-3922-0.

17.

Chemotherapy Use at the End of Life in Uganda.

Low D, Merkel EC, Menon M, Lyman GH, Ddungu H, Namukwaya E, Leng M, Casper C.

J Glob Oncol. 2017 Dec;3(6):711-719. doi: 10.1200/JGO.2016.007385. Epub 2017 Jan 18.

18.

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.

Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, Balch CM, Berman BS, Cochran A, Delman KA, Gorman M, Kirkwood JM, Moncrieff MD, Zager JS, Lyman GH.

Ann Surg Oncol. 2018 Feb;25(2):356-377. doi: 10.1245/s10434-017-6267-7. Epub 2017 Dec 13.

PMID:
29236202
19.

Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia.

Cupp J, Culakova E, Poniewierski MS, Dale DC, Lyman GH, Crawford J.

Clin Lung Cancer. 2018 Mar;19(2):e163-e169. doi: 10.1016/j.cllc.2017.10.013. Epub 2017 Oct 28. Review.

PMID:
29233611
20.

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.

Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, Balch CM, Berman BS, Cochran A, Delman KA, Gorman M, Kirkwood JM, Moncrieff MD, Zager JS, Lyman GH.

J Clin Oncol. 2018 Feb 1;36(4):399-413. doi: 10.1200/JCO.2017.75.7724. Epub 2017 Dec 12.

PMID:
29232171
21.

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update Summary.

Wong SL, Kennedy EB, Lyman GH.

J Oncol Pract. 2018 Apr;14(4):242-245. doi: 10.1200/JOP.2017.028241. Epub 2017 Dec 12. No abstract available.

PMID:
29232158
22.

A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group.

Lyman GH, Poniewierski MS.

J Natl Compr Canc Netw. 2017 Dec;15(12):1543-1550. doi: 10.6004/jnccn.2017.7038. Review.

PMID:
29223991
23.

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L.

J Natl Compr Canc Netw. 2017 Dec;15(12):1520-1541. doi: 10.6004/jnccn.2017.0175.

PMID:
29223990
24.

Clinical prediction rules for mortality in patients with pulmonary embolism and cancer to guide outpatient management: a meta-analysis.

Nguyen E, Caranfa JT, Lyman GH, Kuderer NM, Stirbis C, Wysocki M, Coleman CI, Weeda ER, Kohn CG.

J Thromb Haemost. 2018 Feb;16(2):279-292. doi: 10.1111/jth.13921. Epub 2018 Jan 15.

PMID:
29215781
25.

Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).

Kuderer NM, Poniewierski MS, Culakova E, Lyman GH, Khorana AA, Pabinger I, Agnelli G, Liebman HA, Vicaut E, Meyer G, Shepherd FA.

Oncologist. 2018 Feb;23(2):247-255. doi: 10.1634/theoncologist.2017-0205. Epub 2017 Sep 26.

PMID:
28951500
26.

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.

Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH.

Support Care Cancer. 2018 Jan;26(1):7-20. doi: 10.1007/s00520-017-3854-x. Epub 2017 Sep 22. Review.

PMID:
28939926
27.

Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.

Khorana AA, Vadhan-Raj S, Kuderer NM, Wun T, Liebman H, Soff G, Belani C, O'Reilly EM, McBane R, Eikelboom J, Damaraju CV, Beyers K, Dietrich F, Kakkar AK, Riess H, Peixoto RD, Lyman GH.

Thromb Haemost. 2017 Nov 1;117(11):2135-2145. doi: 10.1160/TH17-03-0171. Epub 2017 Sep 21.

PMID:
28933799
28.

Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.

Lyman GH.

J Oncol Pract. 2017 Sep;13(9_suppl):7s-9s. doi: 10.1200/JOP.2017.026831. No abstract available.

PMID:
28898591
29.

Patient-reported outcomes in acute myeloid leukemia: Where are we now?

Buckley SA, Kirtane K, Walter RB, Lee SJ, Lyman GH.

Blood Rev. 2018 Jan;32(1):81-87. doi: 10.1016/j.blre.2017.08.010. Epub 2017 Sep 1. Review.

PMID:
28888621
30.

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH.

J Clin Oncol. 2017 Oct 1;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789. Epub 2017 Jul 31. Review.

PMID:
28759346
31.
32.

The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review.

Lyman GH, Allcott K, Garcia J, Stryker S, Li Y, Reiner MT, Weycker D.

Support Care Cancer. 2017 Aug;25(8):2619-2629. doi: 10.1007/s00520-017-3703-y. Epub 2017 May 8. Review.

PMID:
28484882
33.

Costs, Trends, and Related Factors in Treating Lung Cancer Patients in 67 Hospitals in Guangxi, China.

Zhou LF, Zhang MX, Kong LQ, Lyman GH, Wang K, Lu W, Feng QM, Wei B, Zhao LP.

Cancer Invest. 2017 May 28;35(5):345-357. doi: 10.1080/07357907.2017.1296156. Epub 2017 Apr 3.

PMID:
28368669
34.

Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement.

Visvanathan K, Levit LA, Raghavan D, Hudis CA, Wong S, Dueck A, Lyman GH.

J Clin Oncol. 2017 Jun 1;35(16):1845-1854. doi: 10.1200/JCO.2017.72.6414. Epub 2017 Mar 30.

PMID:
28358653
35.

American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology.

Zon RT, Edge SB, Page RD, Frame JN, Lyman GH, Omel JL, Wollins DS, Green SR, Bosserman LD.

J Oncol Pract. 2017 Mar;13(3):207-210. doi: 10.1200/JOP.2016.019836. Epub 2017 Feb 7. No abstract available.

PMID:
28282276
36.

Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment.

Peppercorn J, Horick N, Houck K, Rabin J, Villagra V, Lyman GH, Wheeler SB.

Cancer. 2017 Jul 1;123(13):2506-2515. doi: 10.1002/cncr.30629. Epub 2017 Feb 14.

37.

Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.

Khorana AA, Francis CW, Kuderer NM, Carrier M, Ortel TL, Wun T, Rubens D, Hobbs S, Iyer R, Peterson D, Baran A, Kaproth-Joslin K, Lyman GH.

Thromb Res. 2017 Mar;151:89-95. doi: 10.1016/j.thromres.2017.01.009. Epub 2017 Jan 26.

PMID:
28139259
38.

Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: 2016 American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

Lyman GH, Somerfield MR, Giuliano AE.

J Oncol Pract. 2017 Mar;13(3):196-198. doi: 10.1200/JOP.2016.019992. Epub 2017 Jan 24. No abstract available.

PMID:
28118104
39.

Reply to L. Del Mastro and A. Prat.

Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Telli ML, Trudeau ME, Wolff AC.

J Clin Oncol. 2017 Apr 1;35(10):1139. doi: 10.1200/JCO.2016.70.9758. Epub 2017 Jan 17. No abstract available.

PMID:
28095161
40.

Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.

Fust K, Parthan A, Maschio M, Gu Q, Li X, Lyman GH, Tzivelekis S, Villa G, Weinstein MC.

Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):39-52. doi: 10.1080/14737167.2017.1276829. Epub 2017 Jan 20. Review.

PMID:
28064553
41.

Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology.

Kuderer NM, Burton KA, Blau S, Rose AL, Parker S, Lyman GH, Blau CA.

JAMA Oncol. 2017 Jul 1;3(7):996-998. doi: 10.1001/jamaoncol.2016.4983. No abstract available.

42.

PS01.76: Impact of Chemotherapy Intensity on Progression and Survival in Metastatic Non-Small Cell Lung Cancer: A Systematic Review: Topic: Medical Oncology.

Poniewierski MS, Culakova E, Lyman GH, Dale DC, Crawford J.

J Thorac Oncol. 2016 Nov;11(11S):S319. doi: 10.1016/j.jtho.2016.09.111. Epub 2016 Oct 28. No abstract available.

43.

Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE.

J Clin Oncol. 2017 Feb 10;35(5):561-564. doi: 10.1200/JCO.2016.71.0947. Epub 2016 Dec 12.

PMID:
27937089
44.

Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.

Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, Weinstein MC, Somers L, Hoefkens C, Lyman GH.

Pharmacoeconomics. 2017 Apr;35(4):425-438. doi: 10.1007/s40273-016-0474-0.

45.

Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit.

Halpern AB, Culakova E, Walter RB, Lyman GH.

JAMA Oncol. 2017 Mar 1;3(3):374-381. doi: 10.1001/jamaoncol.2016.4858.

46.

Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.

Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y, Reiner M, Lyman GH.

Support Care Cancer. 2017 Feb;25(2):439-447. doi: 10.1007/s00520-016-3421-x. Epub 2016 Oct 12.

PMID:
27734153
47.

Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.

Agiro A, Ma Q, Acheson AK, Wu SJ, Patt DA, Barron JJ, Malin JL, Rosenberg A, Schilsky RL, Lyman GH.

J Clin Oncol. 2016 Nov 10;34(32):3872-3879. doi: 10.1200/JCO.2016.67.2899. Epub 2016 Sep 30.

PMID:
27646945
48.

Predicting neutropenia risk in patients with cancer using electronic data.

Pawloski PA, Thomas AJ, Kane S, Vazquez-Benitez G, Shapiro GR, Lyman GH.

J Am Med Inform Assoc. 2017 Apr 1;24(e1):e129-e135. doi: 10.1093/jamia/ocw131.

PMID:
27638907
49.

Innovations in American Society of Clinical Oncology Practice Guideline Development.

Somerfield MR, Bohlke K, Browman GP, Denduluri N, Einhaus K, Hayes DF, Khorana AA, Miller RS, Mohile SG, Oliver TK, Ortiz E, Lyman GH.

J Clin Oncol. 2016 Sep 10;34(26):3213-20. doi: 10.1200/JCO.2016.68.3524. Epub 2016 Jul 5.

PMID:
27382097
50.

Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking Precision Medicine.

Lyman GH, Moses HL.

N Engl J Med. 2016 Jul 7;375(1):4-6. doi: 10.1056/NEJMp1604033. Epub 2016 Jun 1. No abstract available.

PMID:
27353537

Supplemental Content

Support Center